Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck And Cape Town Target Malaria Drug
by Alex Scott
November 30, 2015
| A version of this story appeared in
Volume 93, Issue 47
Merck KGaA and the University of Cape Town will jointly run a research program developing a potential treatment for malaria. The collaboration is set to extend to other tropical diseases. It will use H3D, the university’s drug discovery and development center, and Merck’s compound library to develop antimalarial drug candidates. Members of Merck’s executive board visited 10 African countries in the past week to underscore the firm’s commitment to the continent, Merck says.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter